A late-stage clinical-trial setback is bad news, but that doesn't necessarily mean it's a good idea to sell any shares of Pfizer or BioNTech right now. Here's what shareholders from both companies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results